Showa University Northern Yokohama Hospital Division of Cardiology, 35-1, Chigasaki-Chuo, Tsuzuki, Yokohama, 224-8503, Japan.
Heart Vessels. 2023 Jul;38(7):889-897. doi: 10.1007/s00380-023-02239-8. Epub 2023 Jan 25.
This single-centre prospective feasibility study (UMIN000030232) evaluated whether zinc supplementation was safe and effective for improving outcomes among patients with acute myocardial infarction (AMI). Within 24 h after successful primary percutaneous coronary intervention, consenting patients with AMI were randomly assigned 1:1 to receive conventional treatment (conventional treatment group) or conventional treatment plus zinc acetate supplementation (zinc supplementation group). The two groups were compared in terms of major adverse cardiovascular events (MACE), and scar size, which was evaluated using cardiac magnetic resonance imaging (CMR) at 4 weeks after discharge. A total of 56 patients underwent randomization (with 26 assigned to the zinc supplementation group and 27 to the conventional treatment group). The two groups had generally similar laboratory findings and clinical characteristics. The two groups also had similar lengths of hospital stay and rates of MACE. Forty of the 53 patients underwent CMR and it revealed that % core zone was numerically lower in the zinc supplementation group than in the conventional treatment group (9.3 ± 6.9% vs. 14.2 ± 9.1%, P = 0.07). This small single-centre study failed to detect a significant reduction in mid-term MACE after AMI among patients who received zinc supplementation.
这项单中心前瞻性可行性研究（UMIN000030232）评估了补锌是否安全有效，可以改善急性心肌梗死（AMI）患者的结局。在成功进行经皮冠状动脉介入治疗后 24 小时内，征得同意的 AMI 患者被随机分为 1:1 接受常规治疗（常规治疗组）或常规治疗加醋酸锌补充剂（补锌组）。两组主要不良心血管事件（MACE）和瘢痕大小进行比较，出院后 4 周时采用心脏磁共振成像（CMR）评估。共有 56 名患者接受了随机分组（补锌组 26 例，常规治疗组 27 例）。两组一般实验室检查和临床特征相似。两组的住院时间和 MACE 发生率也相似。53 名患者中的 40 名接受了 CMR，结果显示补锌组的 %核心区比常规治疗组低（9.3±6.9%比 14.2±9.1%，P=0.07）。这项小型单中心研究未能发现补锌治疗后 AMI 患者中期 MACE 显著减少。
